Distinct clinical endpoints of Staphylococcus aureus bacteraemia complicate assessment of outcome.
Clark D RussellKarla BerryGeorge CooperWynne SimRui Shian LeeTze Yi GanWilliam DonlonAntonia BesuEmily HeppenstallLuke TysallAndrew RobbSimon DewarAndrew J SmithVance G FowlerPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Patients with SAB experience distinct clinical endpoints: (i) early death, associated with multi-morbidity and age; (ii) metastatic (predominantly musculoskeletal) SAB; (iii) endocarditis, associated with late death occurring in older people with multi-morbidity, and (iv) bacteraemia without complications. These distinctions could be important for selecting appropriate outcomes in clinical trials: different interventions might be required to reduce mortality vs. improve clinical response in patients with metastatic SAB.